Curative Biosciences Financials
We suggest to use Curative Biosciences fundamental analysis to find out if markets are presently mispricing the company. Put another way you can use it to find out if Curative Biosciences is indeed mispriced or if you can make any profits on it by purchasing it and then waiting for the market to recognize its mistake and reprise the security. We were able to break down eighteen available fundamental indicators for Curative Biosciences, which can be compared to its peers.
Curative |
Understanding current and past Curative Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Curative Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Curative Biosciences' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Curative Biosciences' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Curative Biosciences. Check Curative Biosciences' Beneish M Score to see the likelihood of Curative Biosciences' management manipulating its earnings.
Curative Biosciences Stock Summary
Curative Biosciences, Inc. focuses on developing and commercializing therapeutics using hemp-derived Cannabidiol. Curative Biosciences, Inc. was founded in 2009 and is based in Miami, Florida. Curative Biosciences is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| ISIN | US23127M1018 |
| Business Address | 801 Brickell Avenue, |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic |
| Benchmark | Dow Jones Industrial |
| Website | curativebio.com |
| Phone | 949 287 3164 |
| Currency | USD - US Dollar |
Curative Biosciences Key Financial Ratios
Curative Biosciences' financial ratios allow both analysts and investors to convert raw data from Curative Biosciences' financial statements into concise, actionable information that can be used to evaluate the performance of Curative Biosciences over time and compare it to other companies across industries.| Return On Asset | -38.44 | |||
| Cash And Equivalents | 982 | |||
| Beta | 8.19 | |||
| Z Score | -32.4 |
Curative Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Curative Biosciences's current stock value. Our valuation model uses many indicators to compare Curative Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Curative Biosciences competition to find correlations between indicators driving Curative Biosciences's intrinsic value. More Info.Curative Biosciences is rated below average in return on asset category among its peers. It is rated fifth in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Curative Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Curative Biosciences' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Curative Biosciences Systematic Risk
Curative Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Curative Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Curative Biosciences correlated with the market. If Beta is less than 0 Curative Biosciences generally moves in the opposite direction as compared to the market. If Curative Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Curative Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Curative Biosciences is generally in the same direction as the market. If Beta > 1 Curative Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Additional Tools for Curative Pink Sheet Analysis
When running Curative Biosciences' price analysis, check to measure Curative Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Curative Biosciences is operating at the current time. Most of Curative Biosciences' value examination focuses on studying past and present price action to predict the probability of Curative Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Curative Biosciences' price. Additionally, you may evaluate how the addition of Curative Biosciences to your portfolios can decrease your overall portfolio volatility.